<SEC-DOCUMENT>0001641172-25-023971.txt : 20250814
<SEC-HEADER>0001641172-25-023971.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814160156
ACCESSION NUMBER:		0001641172-25-023971
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250814
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dare Bioscience, Inc.
		CENTRAL INDEX KEY:			0001401914
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				204139823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36395
		FILM NUMBER:		251218496

	BUSINESS ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-926-7655

	MAIL ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cerulean Pharma Inc.
		DATE OF NAME CHANGE:	20090714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tempo Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070604
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:DARE="http://darebioscience.com/20250814">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_DARE_darebioscience.com_20250814 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250814_20250814 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001401914 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000004" name="dei:EntityCentralIndexKey">0001401914</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="dare-20250814.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-08-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-14</xbrli:startDate>
        <xbrli:endDate>2025-08-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font-family: Arial, Helvetica, Sans-Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="font-family: Arial, Helvetica, Sans-Serif; margin-top: 0pt; width: 100%; margin-right: 0pt; margin-bottom: 0pt"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font: 1pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt"><b>FORM
<span id="xdx_90C_edei--DocumentType_c20250814__20250814_zCKbZdgpzNId"><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d)</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>of
the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <span id="xdx_90D_edei--DocumentPeriodEndDate_c20250814__20250814_zJVRu6ISapV3"><ix:nonNumeric contextRef="AsOf2025-08-14" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 14,
2025</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt"><b>DAR&#201;
BIOSCIENCE, INC.</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: center"><span id="xdx_90C_edei--EntityRegistrantName_c20250814__20250814_zBF7k9UyOVj7" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt"><b><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000011" name="dei:EntityRegistrantName">DARE
BIOSCIENCE, INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20250814__20250814_ztJhlkS01iub"><ix:nonNumeric contextRef="AsOf2025-08-14" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom; width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top; width: 32%; text-align: center"><span id="xdx_90F_edei--EntityFileNumber_c20250814__20250814_ziYqa6MTBgMj" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000013" name="dei:EntityFileNumber">001-36395</ix:nonNumeric></b></span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom; width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top; width: 32%; text-align: center"><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20250814__20250814_ze3KPXPU8RVj" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000014" name="dei:EntityTaxIdentificationNumber">20-4139823</ix:nonNumeric></b></span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(State or other jurisdiction<br/>
    of incorporation)</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(Commission<br/>
    File Number)</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(I.R.S. Employer<br/>
    Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_906_edei--EntityAddressAddressLine1_c20250814__20250814_zyju9qjDEPCe" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000015" name="dei:EntityAddressAddressLine1">3655
Nobel Drive</ix:nonNumeric></b></span><b><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20250814__20250814_zQVfFKhU8Wo9"><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite
260</ix:nonNumeric></span></span></b><b><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><br/>
<span id="xdx_905_edei--EntityAddressCityOrTown_c20250814__20250814_za72zWySSove"><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000017" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span></span></b><b><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">,
<span id="xdx_906_edei--EntityAddressStateOrProvince_c20250814__20250814_zUQsTArorTCc"><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000018" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></span></b><b> <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20250814__20250814_zNKrYjOrdUgh" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000019" name="dei:EntityAddressPostalZipCode">92122</ix:nonNumeric></span></b><b><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><br/>
</span></b><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(Address of Principal Executive Offices and Zip Code)</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <span id="xdx_90E_edei--CityAreaCode_c20250814__20250814_zQV6jUq7rru7"><b><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000020" name="dei:CityAreaCode">(858)</ix:nonNumeric></b></span></span><b>
<span id="xdx_909_edei--LocalPhoneNumber_c20250814__20250814_zaz5TtMlij12" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000021" name="dei:LocalPhoneNumber">926-7655</ix:nonNumeric></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Not
Applicable<br/>
</b>(Former name or former address, if changed since last report.)</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (<i>see</i> General Instruction A.2. below):</span></p>

<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 0.25in"><span id="xdx_904_edei--WrittenCommunications_c20250814__20250814_zFRqXmEu4atj" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-14" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the
    Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90E_edei--SolicitingMaterial_c20250814__20250814_z7qF7w6fzbLj" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-14" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the
    Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90C_edei--PreCommencementTenderOffer_c20250814__20250814_zCrE7sM4u7Aj" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-14" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b)
    under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20250814__20250814_zeIPz2671S8g" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-08-14" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c)
    under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font-family: Arial, Helvetica, Sans-Serif; width: 28%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font-family: Arial, Helvetica, Sans-Serif; width: 28%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font-family: Arial, Helvetica, Sans-Serif; width: 40%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: center"><span id="xdx_90F_edei--Security12bTitle_c20250814__20250814_zXceHCg6snLi" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000026" name="dei:Security12bTitle">Common
    stock</ix:nonNumeric></b></span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: center"><span id="xdx_901_edei--TradingSymbol_c20250814__20250814_zlwA4R0Pf2Uk" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-08-14" id="Fact000027" name="dei:TradingSymbol">DARE</ix:nonNumeric></b></span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_90D_edei--SecurityExchangeName_c20250814__20250814_z7FBLW0XNlI"><ix:nonNumeric contextRef="AsOf2025-08-14" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span></b></span><b>
    <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Capital Market</span></b></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; background-color: white">Emerging
growth company <span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20250814__20250814_zhvKKPExIrQi"><ix:nonNumeric contextRef="AsOf2025-08-14" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; background-color: white">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="font-family: Arial, Helvetica, Sans-Serif; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font: 1pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Item
2.02 Results of Operations and Financial Condition.</b></span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">On
August 14, 2025, Dar&#233; Bioscience, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the
quarter ended June 30, 2025, a copy of which is furnished as Exhibit 99.1 to this report.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
information in this Item 2.02 and in Exhibit 99.1 to this report is being furnished and shall not be deemed to be &#8220;filed&#8221;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject
to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange
Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation
by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.</span></p>

<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 12pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(d)
Exhibits.</span></p>

<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font-family: Arial, Helvetica, Sans-Serif; width: 0.75in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 0.1in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font-family: Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">99.1</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="ex99-1.htm">Press release issued on August 14, 2025</a></span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">104</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cover Page Interactive Data
    File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>DAR&#201; BIOSCIENCE, INC. </b></span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top; width: 50%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dated: August
    14, 2025</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom; width: 5%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font-family: Arial, Helvetica, Sans-Serif; vertical-align: top; width: 45%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>/s/
    Sabrina Martucci Johnson </i></span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Name:</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Sabrina
    Martucci Johnson</span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Title:</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">President
    and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="margin: 0pt 0pt 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVsKwkAMRVfQPYT5lr60Iv20aBGrlCLi72CjDLaTkhlfS3KXTlvEEAjJvSdXiInIaa0aZDgtqwIO2HaNtAgVXpBRn9E5ss02BTcrvCpjWWo7rD8wI8egY+Z+JN19cD6UwTqFcBFE0yBOIIzTZAblTni9npG+qBq1VbIBqWsomTpWaCW/xw8H+SJN7XtIOiIbRTqFyA9H+QNxGMWwp4d8Et8MFEUmvMlQnsiZ7p1zrV4WdU/CqsHWxZmR/rf3BcyFSl4= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Dar&eacute;
Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>DARE
to PLAY&trade; Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in
Q4 2025</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Positive
Interim DSMB Outcome for Ovaprene&reg; Phase 3 Study Supports Continued Enrollment</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Multiple
Grant-Funded Programs Advance, Including to Address HPV and Long-Acting Contraception</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Four
Commercially Available Solutions for Women on the Horizon</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>In
                                            addition to DARE to PLAY&trade; Sildenafil Cream</I>, <I>Commercialization of Vaginal Probiotics
                                            in the Consumer Health Market Targeted to follow DARE to PLAY Sildenafil Cream availability
                                            and Proprietary Monthly Hormone Therapy via 503B Compounding Pathway Targeted for Late 2026</I></B></FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>Creates
                                            Entry into the Estimated $4.5 Billion Compounded Hormone Therapy Market</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>Conference
Call Today at 4:30 p.m. ET</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Q2
2025 Highlights; Near-Term Revenue and Long-Term Value Creation Through Dual-Path Execution:</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>DARE
                                            to PLAY&trade; Sildenafil Cream: Near-Term Commercial Opportunity</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">On
                                            track for Q4 2025 launch through a 503B outsourcing facility</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">First
                                            phase of direct-to-patient campaign launched in collaboration with Rosy Wellness</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Near-term
                                            revenue generation opportunity</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Sildenafil
                                            Cream, 3.6%</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Discussions
                                            with FDA ongoing regarding endpoint assessment for Phase 3 clinical studies of Sildenafil
                                            Cream, 3.6%</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Ovaprene&reg;:
                                            DSMB Recommendation and Positive Interim Phase 3 Results Highlight Potential of Ovaprene,
                                            Investigational Hormone-Free Intravaginal Contraceptive</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Interim
                                            results support Ovaprene&rsquo;s differentiation as a first-in-category, hormone-free, intravaginal
                                            monthly contraceptive</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Independent
                                            data safety monitoring board (DSMB) reviewed interim safety data and recommended study continuation
                                            without modification</FONT></TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">No
                                            new safety or tolerability concerns and no serious safety concerns were identified</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Interim
                                            pregnancy rate of women treated in the study was consistent with the Company&rsquo;s expectations
                                            based on prior postcoital test study of Ovaprene</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Primary
                                            endpoint will assess the typical use pregnancy rate over 13 menstrual cycles, or the estimated
                                            Pearl Index for Ovaprene</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>DARE-HPV
                                            and DARE-LARC1: Progress in Grant-Funded Women&rsquo;s Health Innovation</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>DARE-HPV</B>:
                                            Currently funded by an ARPA-H award and NIH grant; in development as a novel intravaginal
                                            therapy to treat persistent high-risk genital human papillomavirus (HPV) infections in women
                                            and reduce risk of cervical disease</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>DARE-LARC1</B>:
                                            Preclinical development expected to be fully funded by a foundation grant; investigational
                                            long-acting contraceptive intended to offer multi-year protection with remote pause/resume
                                            capability; $6 million grant installment received in July 2025</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Ongoing
                                            Actions to Make Three Additional Solutions Available Commercially</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Two
                                            non-prescription vaginal probiotics designed to support vaginal microbiome health, complementary
                                            to Dar&eacute;&rsquo;s prescription offerings; availability targeted to follow DARE to PLAY
                                            Sildenafil Cream availability</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9676;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>DARE-HRT1</B>:
                                            Proprietary monthly intravaginal ring designed to deliver bio-identical estradiol and progesterone;
                                            Dar&eacute; is pursuing both an FDA approval pathway and a 503B compounding opportunity to
                                            accelerate patient access while continuing to generate the data necessary to seek FDA approval
                                            and support long-term value creation; 503B compounded solution targeted for late 2026</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>SAN
DIEGO, August 14, 2025 (GLOBE NEWSWIRE) &ndash;</B> Dar&eacute; Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole
focus of closing the gap in women&rsquo;s health between promising science and real solutions, today reported financial results for the
quarter ended June 30, 2025 and provided a company update.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&ldquo;Dar&eacute;
is rapidly transitioning its business model by executing on a dual-path strategy designed to unlock both near-term revenue and long-term
value,&rdquo; said Sabrina Martucci Johnson, President and CEO of Dar&eacute; Bioscience. <FONT STYLE="font-weight: normal">&ldquo;</FONT>With
the anticipated launch of DARE to PLAY&trade; Sildenafil Cream through a 503B outsourcing facility in Q4, followed by other commercialization
efforts including DARE-HRT1 and vaginal probiotics, we intend to build a robust commercial foundation. At the same time, we are advancing
a differentiated pipeline through development, with grant-funded programs that target unmet needs in contraception, HPV, and pre-term
birth. With four potential on-market solutions and a rich clinical pipeline behind them, we believe this is a pivotal time for investors
to take a close look at Dar&eacute; and the growth potential of our portfolio.<FONT STYLE="font-weight: normal">&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Financial
Highlights for the Quarter Ended June 30, 2025</FONT></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Cash
                                            Position:</B> As of June 30, 2025, Dar&eacute; had approximately $5.0 million in cash and
                                            cash equivalents, and a working capital deficit of approximately $12.6 million.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Subsequent
                                            Capital Raise:</B> After quarter-end, Dar&eacute; received approximately $17.6 million in
                                            net proceeds from sales of its common stock, primarily through its at-the-market offering
                                            program, and a $6.0 million grant installment payment. The additional capital significantly
                                            strengthens the company&rsquo;s balance sheet, enhancing the company&rsquo;s ability to execute
                                            its dual-path strategy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>General
                                            and Administrative Expenses:</B> $2.4 million in Q2 2025 compared to $2.5 million in Q2 2024,
                                            with the year-over-year change primarily attributable to decreases in personnel costs, stock-based
                                            compensation expense, and general corporate overhead, partially offset by an increase in
                                            professional services expense.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Research
                                            and Development (R&amp;D) Expenses:</B> $1.4 million in Q2 2025 compared to $4.9 million
                                            in Q2 2024, reflecting a decrease of 71%, primarily due to an increase in contra R&amp;D
                                            expenses (reductions to R&amp;D expenses due to non-dilutive funding awards), as well as
                                            decreases in manufacturing costs related to Ovaprene and development costs related to Sildenafil
                                            Cream, 3.6%, partially offset by increases in costs related development activities for other
                                            clinical- and preclinical-stage R&amp;D programs, including DARE-HPV and DARE-LARC1.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">References
to Section 503B, 503B, Section 503B compounding, 503B compounding pathway, and similar terms refer to Section 503B of the Federal Food,
Drug, and Cosmetic Act (FDCA) and the production and supply of compounded drugs by Section 503B-registered outsourcing facilities without
patient-specific prescriptions in accordance with Section 503B. Dar&eacute; encourages investors to review the more detailed discussion
of its financial condition, results of operations, liquidity, capital resources, and risk factors included in its Form 10-Q for the quarter
ended June 30, 2025, filed today with the U.S. Securities and Exchange Commission (SEC).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Conference
Call</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&eacute;
will host a conference call and live webcast today, August 14, 2025, at 4:30 p.m. Eastern Time to review its financial results for the
quarter ended June 30, 2025 and to provide a company update.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To
access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll free). The conference ID number for the call is 2684883.
The live webcast can be accessed under &ldquo;Presentations, Events &amp; Webcasts&rdquo; in the Investors section of the company&rsquo;s
website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install
any necessary software. The webcast will be archived under the same section of the company&rsquo;s website and available for replay until
August 28, 2025.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>About
Dar&eacute; Bioscience</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&eacute;
Bioscience is a biopharmaceutical company driven by a mission to challenge the status quo, making women&rsquo;s health a priority. Dar&eacute;
believes that innovation does not have to start from scratch. The company&rsquo;s goal is to bring to market as soon as practicable innovative
evidence-based solutions that address decades of unmet needs in women&rsquo;s health and enhance outcomes and convenience, primarily
in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. The potential
products Dar&eacute; identifies, in many cases, already have clinical proof of concept or existing safety data for the active ingredient
that the company leverages. This provides optionality and flexibility, in many cases, in how Dar&eacute; seeks to bring solutions to
market in ways designed to optimize access for women in a fiscally responsible manner.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
first FDA-approved product to emerge from Dar&eacute;&rsquo;s portfolio of women&rsquo;s health product candidates is XACIATO&trade;
(clindamycin phosphate) vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients
12 years of age and older, which is under a global license agreement with Organon. Visit www.xaciato.com for information about XACIATO.
Dar&eacute;&rsquo;s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene&reg;, a novel, hormone-free
monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel
cream formulation of sildenafil citrate, the active ingredient in an oral erectile dysfunction drug for men, to treat female sexual arousal
disorder (FSAD); and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
To learn more about Dar&eacute;&rsquo;s full portfolio of women&rsquo;s health product candidates and mission to deliver differentiated
therapies for women, please visit www.darebioscience.com.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&eacute;
Bioscience leadership has been named on the Medicine Maker&rsquo;s Power List and Endpoints News&rsquo; Women in Biopharma and Dar&eacute;&rsquo;s
CEO has been honored as one of Fierce Pharma&rsquo;s Most Influential People in Biopharma for Dar&eacute;&rsquo;s contributions to innovation
and advocacy in the women&rsquo;s health space.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&eacute;
may announce material information about its finances, products and product candidates, clinical trials and other matters using the Investors
section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Dar&eacute;
will use these channels to distribute material information about the company and may also use social media to communicate important information
about the company, its finances, products and product candidates, clinical trials and other matters. The information Dar&eacute; posts
on its investor relations website or through social media channels may be deemed to be material information. Dar&eacute; encourages investors,
the media, and others interested in the company to review the information Dar&eacute; posts in the Investors section of its website and
to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels
the company may use to communicate information will be posted in the Investors section of Dar&eacute;&rsquo;s website.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&eacute;
cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.
Forward-looking statements, in some cases, can be identified by terms such as &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;design,&rdquo; &ldquo;intend,&rdquo; &ldquo;expect,&rdquo;
&ldquo;could,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;positioned,&rdquo; &ldquo;pursue,&rdquo; &ldquo;seek,&rdquo;
&ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;objective,&rdquo;
&ldquo;on track,&rdquo; or the negative version of these words and similar expressions. In this press release, forward-looking statements
include, but are not limited to, statements relating to Dar&eacute;&rsquo;s go-to-market strategies; Dar&eacute;&rsquo;s plans and timing
for making its proprietary formulations available by prescription in the U.S. as compounded drugs via Section 503B and for launching
branded consumer health products; the market opportunity for those products and their ability to gain market acceptance; expected timing
of revenue from sales of those products; Dar&eacute;&rsquo;s intent to continue to pursue an FDA approval pathway for those product candidates
it brings to market under Section 503B; plans and expectations with respect to Dar&eacute;&rsquo;s product candidates, including clinical
development plans, trial design, timelines, costs, milestones, targeted indications, clinical trials and results, regulatory strategy,
and U.S. Food and Drug Administration (FDA) communications, submissions and review of applications; the clinical potential of and market
opportunities for Dar&eacute;&rsquo;s product candidates; Ovaprene&rsquo;s potential to be the first FDA-approved hormone-free intravaginal
monthly contraceptive; the importance of the interim results from the ongoing Phase 3 clinical study of Ovaprene to Dar&eacute; and Ovaprene;
potential strategic partnerships and third-party collaborations; expectations regarding existing collaborations; the sufficiency of non-dilutive
grant and other financial award funding to advance development of specified product candidates, including through specified milestones;
and the impact of post-second quarter-end funding on Dar&eacute;&rsquo;s ability to execute its business strategy. As used in this press
release, &ldquo;first-in-category&rdquo; is a forward-looking statement relating to the potential of a product candidate to represent
a new category of product if it were to receive marketing approval for the indication for which it is being developed because Dar&eacute;
believes it would address a need in women&rsquo;s health that is not being met by existing FDA-approved products. Forward-looking statements
involve known and unknown risks, uncertainties and other factors that may cause Dar&eacute;&rsquo;s actual results, performance or achievements
to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in
this press release, including, without limitation, risks and uncertainties related to: Dar&eacute;&rsquo;s ability to raise additional
capital when and as needed to execute its business strategy and continue as a going concern; Dar&eacute;&rsquo;s dependence on grants
and other financial awards from governmental entities and a private foundation; limitations on Dar&eacute;&rsquo;s ability to raise additional
capital through sales of its common stock or other equity securities due to restrictions under SEC and Nasdaq rules and regulations or
contractual limitation; Dar&eacute;&rsquo;s inexperience, as a company, in and lack of infrastructure for commercializing products; Dar&eacute;&rsquo;s
reliance on Section 503B-registered outsourcing facilities and other third parties to bring DARE to PLAY&trade; Sildenafil Cream and
other solutions to market as compounded drugs or as consumer health products and facilitate access to such products and the risk that
those third parties do not perform as expected; the risk that the FDA could stop permitting Section 503B-registered outsourcing facilities
to compound the drug substances in the proprietary formulations Dar&eacute; intends to bring or brings to market; the degree of market
demand and acceptance for the products Dar&eacute; brings to market; Dar&eacute;&rsquo;s reliance on third parties to manufacture and
conduct clinical trials and preclinical studies of its product candidates and commercialize XACIATO&trade; (clindamycin phosphate) vaginal
gel 2% and future FDA-approved products, if any; the risk that the current regulatory pathway known as the FDA&rsquo;s 505(b)(2) pathway
for drug product approval in the U.S. is not available for a product candidate as Dar&eacute; anticipates; Dar&eacute;&rsquo;s ability
to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines;
failure or delay in starting, conducting and completing clinical trials of a product candidate and the inherent uncertainty of outcomes
of clinical trials; Dar&eacute;&rsquo;s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients,
to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety
and efficacy of its product candidates; Dar&eacute;&rsquo;s dependence on third parties to conduct clinical trials and manufacture and
supply clinical trial material and commercial product; the risks that positive findings in early clinical and/or nonclinical studies
of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate and that
interim data or results from a particular clinical study do not necessarily predict the final results for that study; the risk that the
FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Dar&eacute;&rsquo;s
interpretation of or conclusions regarding data from clinical studies of its product candidates; the risk that development of a product
candidate requires more clinical or nonclinical studies than Dar&eacute; anticipates, or that the duration of a study or number of study
subjects must be significantly greater than anticipated; the loss of, or inability to attract, key personnel; the risk that developments
by competitors make Dar&eacute;&rsquo;s product or product candidates less competitive or obsolete; difficulties establishing and sustaining
relationships with development and/or commercial collaborators; failure of Dar&eacute;&rsquo;s products or product candidates, if approved,
to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; Dar&eacute;&rsquo;s ability
to retain its licensed rights to develop and commercialize a product or product candidate; Dar&eacute;&rsquo;s ability to satisfy the
monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and
related intellectual property related to its product and product candidates; Dar&eacute;&rsquo;s ability to adequately protect or enforce
its, or its licensor&rsquo;s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Dar&eacute;&rsquo;s
product candidates which could expose its products to competition from other formulations using the same active ingredients; product
liability claims; governmental investigations or actions relating to Dar&eacute;&rsquo;s products or product candidates or the business
activities of Dar&eacute;, its commercial collaborators or other third parties on which Dar&eacute; relies; the effects of macroeconomic
conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Dar&eacute;&rsquo;s
ability to raise additional capital or on Dar&eacute;&rsquo;s operations, financial results and condition, and ability to achieve current
plans and objectives; Dar&eacute;&rsquo;s ability to maintain compliance with Nasdaq&rsquo;s continued listing requirements and continue
to have its common stock listed on The Nasdaq Capital Market; the impact of pharmaceutical industry regulation and health care legislation
in the United States and internationally; global trends toward health care cost containment; cybersecurity incidents or similar events
that compromise Dar&eacute;&rsquo;s technology systems or those of third parties on which it relies and/or significantly disrupt Dar&eacute;&rsquo;s
business; and disputes or other developments concerning Dar&eacute;&rsquo;s intellectual property rights. Dar&eacute;&rsquo;s forward-looking
statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All
forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Dar&eacute;&rsquo;s
risks and uncertainties, you are encouraged to review its documents filed with the SEC including Dar&eacute;&rsquo;s recent filings on
Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of
the date on which they were made. Dar&eacute; undertakes no obligation to update such statements to reflect events that occur or circumstances
that exist after the date on which they were made, except as required by law.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Contacts:</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Dar&eacute;
Bioscience Investor Relations</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">innovations@darebioscience.com</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Source:
Dar&eacute; Bioscience, Inc.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&eacute;
Bioscience, Inc. and Subsidiaries</FONT></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Condensed
Consolidated Statements of Operations and Comprehensive Income (Loss)</FONT></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(Unaudited)</FONT></P>



<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Three
    months ended June 30,</FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2025</FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2024</FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Revenue</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; width: 60%; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Royalty
    revenue</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 16%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(21,172</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 16%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">22,438</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Total
    revenue</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(21,172</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">22,438</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Operating
    expenses</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2,377,866</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2,448,130</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">1,428,762</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">4,933,774</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Total
    operating expenses</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3,806,628</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">7,381,904</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Loss
    from operations</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(3,827,800</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(7,359,466</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Other
    income (expense)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Sale
    of royalty and milestone rights, net</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">20,379,376</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Other
    income (expense), net</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(188,683</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(109,254</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Net
    income (loss)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(4,016,483</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">12,910,656</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Foreign
    currency translation adjustments</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">12,893</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">14,563</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Comprehensive
    income (loss)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(4,003,590</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">12,925,219</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Income
    (loss) per common share:</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Basic</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(0.45</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">1.53</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Diluted</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(0.45</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">1.52</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Weighted
    average number of shares outstanding:</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Basic</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">8,871,155</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">8,411,242</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Diluted</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">8,871,155</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">8,476,231</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&eacute;
Bioscience, Inc. and Subsidiaries</FONT></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Condensed
Consolidated Balance Sheets Data</FONT></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>June
                                            30,</B></FONT></P>
                                                                                <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>2025</B></FONT></P></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>December
                                            31,</B></FONT></P>
                                                                                <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>2024</B></FONT></P></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(unaudited)</FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cash
    and cash equivalents</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 2%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">5,035,006</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 2%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">15,698,174</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Working
    capital (deficit)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(12,618,726</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(3,165,204</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Total
    assets</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">12,979,525</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">22,101,131</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Total
    stockholders&rsquo; equity (deficit)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(12,733,260</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(6,012,089</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !R '@# 2(  A$! Q$!_\0
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MHHH ***C=F4$@#(Q]XD D]L@'\\>V.E&W]=@_K<KWPS;RGN(I3GD_P#+*4=
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M&0<C XY/XW0>GODCTQD8_3'ZUC6%VZ6]A'/!+#(]K;*RR*4VO]G0LF&"G<C
MA@>5P0PS@G523=@@'D$_F2?7D\'TZBOTFE?DI7NFJ5/F3NO^7<&T^97O?SEJ
MFG+F32^+G*+G4Y6FE5JKW;-65:KM;I9)Q=DG%Q<;Q<62T4F0>._IW_*E'/Z_
MH<5N 4444 %%%% !1110 444G?/M_P#JX]^<4 (S <%E7@]2./3@G\?P]Z^:
M?CE^T)I/PJVZ1IT$>N^,+NW$\.E-*8K'2;5LB/4-=G0&5$E.3::=;E;J]4%W
MEL[<+</['X\\3VG@KPEXB\77L8EBT#2KB_\ (8E%N9XHV6TM-V&*?:[QX;8O
M@^6)M^&*@5^='[/OP\D^,WCS7?&GCQAKFG:1=6^I:S%<QE[?Q!XBU>22:UL)
MXWS&=,T^WMS/<6!9X_LQTW3MIM'D4^WE.!PU6GB\SS!MY=@.2%2E&ZJ8K$55
M>GAX--:-.+G)/1247HVU\)Q=GN98?$99PYD#I1SW/*E3DQ-9<U/+<NH6^N8Z
M46FO:Q7/&@Y1G%<DZD8RFJ=NA^']C^T!\7/%WA;QSKNH:H/"&F:W9:TYO;R7
MP_X?N[&TE6YDAT;0;8 ZN&$>VWN)[>>$D$R7ZI*F/S5_:'T[P?J'P \$/XP\
M7R^#[.Q^+6HWUG?CP;J7C&VN&3X6VINX;V'1]0LM1TX0VB">*>VLM9EO<M;1
MV<1Q*?Z0I8O+MYE"JJ+;RQJJ?*B*J':BH %"J,A54!4&%48Q7\Q?[7AS^S#X
M4XZ?$SQ!CVS\&XN?<\YR>_-?DWTC<X]M]'WQ:Q;R[ PH8/+.'J=+ 06(HT)4
MI<2994Y:U;!8K"8MU5?3$8?$4*JE9\U2$7"?ZA]&CAAY;])[P+P']LYIB<;F
M.9\9U\9FU>>%Q6)>(7!F;PY\/0S#"YA@Z=)*+@\-7PU:G5IMJ<85&IQ['6?A
MQ^WE^Q%;KXNT'Q+KE_\ #_3UCOKR]\+:UJ7C_P"'-A901K-'-XA\'^([:WN?
M#MH8)2+B^71M*BM1P-3=1(UO^H?['7[=7AO]I:&?PEK]E#X+^+6EV*WUQX=M
M[LW&A>)],BW"ZUSP;?7+"[D2SVH^KZ!?>=J>DQRPW$,^J61EOH_OA85GTR"%
MD5UELH8F4CY61XD2164Y1E="597#*0S*58-@_P YO[<_P+N/V2/C;X&^+7P6
M=/!VC>+-4O/$/@ZUTR,1V7@GX@>&9;.YU'1+2UC*0Q>&-<L=1CNK#1HS#:)I
MO]OZ"EM!IEG:H_\ .O$&1<4?1QI8+C/@_/\ B'B?PPIXK T>,>!^(,<\VQ&3
M8''UJ-!9MPYFF+E"KAE1Q.)Y9TKTY1J3PWUVEC<)B*N+P_\ 6/#6>\+?29K8
M[@/C+A[ASA?Q:Q.$Q^(X(\0>&LMIY+A<\S# 4<1B%D?%&58&E#"XF>*PU!R^
MLR565:$,1/+ZV79AA*.&QG](-M+NB5F8-G)SUX&"!QD< ]CC/IUJV#D CO7D
MOP5^)>G_ !@^%/@'XG:5!):V?C7PSINNFQ:4S-IM[<PJ-3TOSWBB><Z5JD5[
MIWG-$C2_9?-9%+!1ZR@(4 YSSUZ]3_D>U?UYE^,P^8X+!YAA*T<1A,=@\+C<
M+B(*2AB,-B\/0Q.'KQ4_?4:U'$4JBC+WX^T<9VG"2/X_Q.%Q. Q>+R_&T98?
M&X#%8G XS#U&I5,/BL%B*^$Q-"<EI*5&OAJU)S7NU/9\\?=J1;=111788A11
M10 4444 %,/)..Q3/OR?\1^5/I./3T_^M^7Z4":O_7D?.W[42W3?!GQ8;7)5
M6T=[H@$?Z(NL6IF#G=S%RH88!PQ(Y''G/[&,D#> /$,<6//B\;WGVSYOG!;1
M])^RL5!R 8E95SUVDJ2,X^I?&'AVR\6^'=<\,ZDA^Q:_I5UI5Q(L:R26QN49
M(;V$.-IGLYVCN[<GA)X(WX R/S1^$/CG4OV>_B3K_A7QS#-;:7>S6VE>)6A2
M5HK&ZLI)3HWBFTC*F672YH+F1IYHHVE?3;I97C:6Q$(^DRWFQO#^99=15\3A
M\52Q\*2TE7I0C3A+E?VO9RBTXO?W6E9M'YAQ'*.3<=\-\08R3IY7BL!C<CJ8
MAQ;I8/&5D_J[J2L_9QK^V4E.VKA56O*^7]3;O_CWF]3%+D\X)\MP1TX/ /&,
M_P _YA/VNP1^S%X5'_53-?[8_P":.1>PK^FN*_M;_3A=6EU;WEI=63W-K=VU
MPEQ!<02QL8YH)8V:.2-E.5>-F0X(5B :_F6_:[S_ ,,Q>%.__%R_$ !'(X^#
M<?\ +OGIR>!T_ _I#W_XEO\ &5-6:R_AY-76C7$.5*WJFTK6W:2U:3_H[Z/4
MD_I8_1^DI1:EC^-)1::<91?!V<-3A).TX-23C.+<6M;VU/Z=;3FSM5SC-K;_
M ##J"(8_8\'&#WX%?E7_ ,%>)],'P%^'EO,T)U.X^,.E2:9$2JW#"W\)>+#J
M+QJ!YK1):S".Y9" #-"'ZI7Z>7VKZ7H?AZ;6-7U2QT?2],TN.]U+5=1O+:PT
M_3K2&!'FO+Z\NGBM[6WACR\L]Q(D4:9+. <G^<+]JOXR>(OVZ/VA/!?PU^#4
M$VH>'=)N-1\*_#V34(;JVAU;4]6N+27QA\1M6@$?VJQ\-V=KIEJ\,MRD=W#H
M&E/<QV]O>:Q/:CXGZ27%.7Y3X7YGPM&,L?Q/Q]A<'PSPUD6%2K9CF.(QN*RN
M-6O0PT7*HZ&$A3@GB'&%+ZSB\)AXU93J5?8?I_T8.%\PS7Q8RCBR:6"X4\.,
M3BN+>+.(L3>EE>583+\-FLZ&'Q&*E%4(XG'593]GA^=U8X;!XO%3I1ITJ2Q'
MZX_\$Y8-1C_9$^%YOBY$I\5S:<SDKC2Y?%NL&U ( &S*S$#H&SMXR!]Z#C]?
MU.:\Z^%WP_T/X7?#OP9\.?#JD:+X+\-Z7X=L9I$ABGNUTVTC@EU&ZCA"Q)>Z
MG<++J%YY8"&\NKAQD-7H:]!^/?/<\YXSFOV;@K):_#?"'"O#^*JJMBLCX<R3
M*<35BU*$\1E^787#XAPDKITUB(UXP:=G"G3:TE$_%.,<ZH\2<8\6\18:G*EA
M<^XFSW.<-2FFJD,-F.:XW%8:-2,DI1J/#U*$ZD6E*-2I44E>,AU%%%?4'SH4
M444 %%%(<=#WXH ">"?3/Z4 D]01QZ_T_P FF.0$8]PN03S],Y!R.,G@G /!
M-<)H/Q(\'>(O$NK>$-)UVUO/$>A+<MJVE1PW45S9"UGAMIS*\MM% 1#/<01M
MY<KG=+&0"IS51A.2FXTYS5.'/4E&$I1IPNHJ52234(N344Y65[*^J,*N)H4*
ME"E6KT:-3$U'2P].K5A3GB*JBYNE1C.495:BA%S<(*4N5.2BTG;OB,@^IX^G
M\^F<UX5\8_@9X;^+5E!/>/\ V+XCTZ%X]-\1VL EN4@9C*NGZC"KP'4],68F
M6.WFECDLYGEDL9K=IYS)[KGKGCW[?Y_SS2,H92O0<?I_/\:NAB*V&K4Z^'JS
MI5J3YH3IRLUI\+WC*,K6E&2::T:2=S',,NP6;82M@,QPU+%X3$1Y:M&K&\96
M=XM->]"<&DXU*<HS@TW&5FU+\NK?PA^TQ\$#<VOAY-3U#06+L\?A\_\ "5^&
M)B1A[J+1;R$7^D3RJV;DQV.ERRR8S/=;/,;\^OVJ/ 'BS4O@?X.\.67@SQ;?
MW+_&;6;673K'PUKM[?+97'PN@L/,DA@LC/&DF]X$N'2.-Y5:)'$@(K^D-(%!
MR"P9<#.><?CGJ0.@ QC@U');*"\GFR99=I&\X/48QDC@]1C![YP17@^)^5KQ
M-\/>*. L=*CE,.*<-@L+BLZP&'IU,716"S+ YC"L\)5E2PN(J.>!5+EG4I)>
MWE54^:FK[>$M/_B$7B=P;XDY96Q^>_ZE8K,L1EW#><9A5EE\UF>58_*ZE&&/
MHPGC,-1I1QT:RY*%2I+V,:2C:<FOYQ+_ .%/_!0[]LVXM-.\<6^O:%X-MYXF
M2#QVY^&7PYLGCP(;YO"FF6,FM>)[N!85^Q2RZ#K5Q:7!7RI],BN9;MOUU_93
M_8P\ _LOZ-=W>FS+XM^(FNV<-IXC^(.HVJVMY-9Q.9_[#\/6.ZZ_X1SPZ;LK
M//8V]U<3ZG-!9S:O=7IL+!+3[%B@5/+ 9R5[D@DYZ[L !N>?;MTQ5L ;1WP3
MG'U/_P!8]O6ORW@?P.X7X0SN7%F8YCGO''&LX*"XIXNQW]H8O!TW&4.3*L%[
M^!RNU.3HQJX=5,3&FYQHU\/[2I*I^W<<>.G%?&611X/P&6<.\!\#PJ>TEPCP
M5@/[-P&/J7A+VN=8Q\F/SANK"-94,4X8558QG6P^*E3IJE%%"40*0H;+,Q!+
M#+$$C<<,>>^.G3J14X&!_GO2_P"?Z?Y]Z*_:DDM%LE9*^R5EU\DOUN?BZ26G
MZ)?EW=WZM]P/'Z?J<4?R]?\ /^>:0]/Q7^8_S_*N-\8>/O"G@*Q34_%VN6FB
M6<]PMM;-<K+)+<S$ F.VMK>.>YN'52&D\J)Q$N&D*+S51C.<HPIPG4J3=H4Z
M<)5)R?:,(IMNUW\C.O7HX:E.OB*M*A1IKFJ5JU2%&E3CMS5*E6=.G"-[*\I)
M79V(.>V!R/?([8^GY8/L:*Y+PEXRT;QOI<.N^'+J6^T:Z:5;2^DL[FRBNQ%L
M!FM5O(8))[9F9T6YB5X792JN=IHH<9PE*%2+A.+<90FG&49)V:<7=IIZ-='I
MNF%&O2Q%*%:C5IU:52*E2J4VY0J0>TXOE5T];-J-U:23C*,I=0)HL AQSC;@
M99A@=N">XZ?3G%><:U\8_A;H%VUCJ_C_ ,*6-[&2LEO-K%LTB.F"P=8C+L=<
MG<K8*]" :^6/BWXX\;?%?XAR_!'X:W[Z38:>)8_&&KQ3/%'.T"Q-JD=W=6F+
MM=%T?S!9S65JT4VL:G<&T9U@ !],\,?LD_"72[%(-6L-4\4WGEQF6_U/6-3T
MX-* -[V]EH=UIT5NK,.$DDNI$!P9W Q7KPR_!X:C1K9MB<13GB::JTL'@:-*
MMB849W=*I7JUYPH4E5BN:,.7GE&STYHV^/J9_G6:8O&X7A;+<!7PN78JI@L7
MG&<XROA\!4QE'2MA,OHX&E5Q6+E0G>G6Q%Z5"G4C*$544HR7OGA_QAX5\76D
MEUX8\1:/KUNBXD?2[^WO?*W9V^:D;&2(-G(\U55N3DX./CKX)C_C*7XQX4?\
M>OB4X( _YF#P]SGKCD%AWXW=*TO'?[+Y\-*_B_X(:SKGACQ=I/F7=KI8U2XN
MHM06']Z]I8WEV7F6YDPZ16>J27^FZCO:UO4CCD#+Y[^RCKU_XF^-GC7Q%J8B
M74M<\*:GJ-_%#$\,2W<^M>'?M!C@?,EN'E5W,+DM"[-&%55P/3PN&PL,MSO%
MX#%SKX>> IT'2KTOJ^,H5%BZ-1*K"$ZE*=.48S4*M*2@W%JRYHI?.YIFF:UN
M(>"\LSO+*>!QM//I8REB<'7GB\JS##++L;1E4PM>K3I5\/7I5W3C6PF*@ZL:
M<U4A4E%^[^CS.BCYB!R <X/?'/;G'^':N4\2>.O!WA"&.;Q-XFT301,H:'^U
M-0M[1Y4S]](I&$KQ[OE,BQ[,\%A7C/[1_P 8)OA3X=L4T18I?%OB9Y[70@\3
M70L(;,*-0U:2S4.MS);M=VL&GVTD<JW-_<H'BE2%XI/,/AY^RI!JEO%XI^,V
MI:SXB\3ZJ!<WFE-K%TBVGFJC_9]6U6-_MVHWZ[RDZVEU;V-F5:UM!-%&';R<
M-E]#ZM#'9AB)X7#5:E2E0IT*:KXK%.E:-25*G*<*=*G!M1=2L^64M(J5FU]3
MF7$&/>9RR+A[ 4<QS*A1HU\PQ.-Q,\)E>54JZYL-'$U:,*M>OB\534ITL)0C
M"IR)SE-12D_I?1?C!\+_ !!>KIVC^/O"=_>R-LCMH-6M5FD=LA%C61H][MT5
M4WL>BY) /I(= I)88!P<Y SQUR ><@DX[U\M>)?V1OA)K%@T.E6.I>%[T(XM
M[^QU?4]5C5Y%)47-CKUWJ,5Q$"07CCDM=Z@_O4)&/-/A)XY\:_"?XCK\$/B9
M?R:OIE\88?"&KW$\LRP-<B8Z0EK=79,\NBZND$MI%:7+E]%U2!-/M'EM'D,%
MSR_ XJE7GE.*KU*N&HNO6P6.I4:.)G1B[3JX:I0J5*5?V<;U)TURSC",MVE?
M"GG^<Y7C,'A.*,MP-##YC7AA,+F^3XK$8C 4\95;5'"8ZCC:5+$X9U](T<3S
M2H3K25-PA\1]X%E52Y( P/F[\\9] ",8^M4H=4TRZ>2&VU"SGE@W>?%!=02S
M1;&,;^=''(SQ;'!1_,52KC80&XJQ+S!]W:2JG!.=I7:1CKR,=>>0,YK\C]/\
M2>.='^)GQ5\/_#F.5/%/C[QGXB\/VUY;3&*[L(+?QAK-Y=2VL\JO#9%HF(EU
M610VE6J37,)%QY+)EEF6RS-8SDK4Z3PE&C7YZB_=.-2LZ4Y5)73A&E!2J)Q4
MI3Y7"*3E%G7Q-Q/#AJ64NK@JV,AF6+Q.#<<-S5,5&I2P<J^'IX;#Q@_K5?%8
MCV6%A1YZ7+[3VG,XP:/T_P!>^)/@'PU?VNE:[XNT#3=4O+B&VMM-NM2@6^GN
M+B58;> 6B&2<23RO''"CQAI68! 2:[@L%!)( !ZG@8[D_CG\?SKY$\ ?LE^$
MO#[:7KWBK4]2\3^*[*\L]7>XCO+JQTJ'5;&X@O86AMAF\U*..\A1VN-2N2UZ
M!NFMXQ*\8Z_]H?XR3?"SPM;+HZ1/XH\2275MH(EC6Z2S@LD235-8EM.3<FR%
MS9P6EJP=9K^\@1X9(XY$)/!X:OB<-@\JK5L95J7A4J5Z4,-0=1.[E13E*2H0
MIQE.<ZS4ERMJ*3BFZ&=9E@LKS#..*<%@\HPV'A2KT,+A,7/,,7"FXQBZ&*GR
M4</4QM3$U*-&A1PMX2E5Y')RA.2]6\7>-O"WA.U:;7O$_A[09)8':T_MS4HK
M2.60<JY@\Q;F2&-F0RM#&&VY =6.1\;:%X1\ ?$SXA+XC^)?QN\&_$=XBJZ3
MX/TU_P"Q='A4R))%IRVNH:I<M+I8&&EL+=5FUF>21M6N+R-FA;0\ ?LSZ7K$
M7_"5?&CQ!?\ B#Q1JACN[O1W\020"R\X-(+?5]2AG-Y<WR!U6XMM/N+2PL71
M;6W,\47F'N_$?[+?P4UBPEATB&;PM?!':WU'3O$5YJ(2?!*//9:Y?ZA#<(I/
M(26TE91A9XCMQZ-+^S<OE6HTLQQTJ]2'L*N-PV7T?90BTXS5"5:?UM0?,XRJ
M472G."DE:,M?FL;'B7B&CA,9BL@R-8*A5AC<+DN:9_F%+$UG&U2E+,J&%A_9
M7UB"4)4L+CH8RAAZG,JE.,TYTOJJVBMH(HX+>*WB2&-(H8X8DB2*%%"QQI&B
MJD<<:!41$ 0!0JJ N 5\*?"+QWXQ^$_Q%C^"GQ%U4:UI&HF&#P?KWVAKE(9+
M@,-/2TNY7:X&CZH$^R1V%U(\NB:G$MG;.UJX(*\C'8"6!K*'/#$TJL(UZ&)H
MQFX5Z4]I\K7/3E=.-2G4O.$TTW)--_99#GN'SK!SKJC++\3AJ]3!X_+\9*E3
MQ&!QE!152@VI>SJT^5QJ4*U)^SJT9TYQ232(/V5FAMOBY\<=/UEE/B:6^DD0
MR#;-+%:>+_$[>(6A!"E4DN[[0;B0JJK+$]JX"B-E7[X"[ H[ CZ_C] #T)R?
M7K7Q1\9_A%XX\/>,T^-'P?BGEUZ(F7Q%HD$23SWDODB*>_M;,R ZI:ZA:C[/
MK.D1LMY)(D-[8"6X'[A=$_;,\(1P&W\8^&O$>@:[;*D=[;:?!;:C:-)&NQFC
M2^NM*U6W#L'80SV4JQ]&N7 WUZ^/PF(SJI2S++J?UMSP^&HXG"TY1^LX2OA\
M/2P[BZ+E!RH35)2I5:7-&S<9)-<[^/R'.,%PA2Q'#O$57^RGAL?F.(R_,L7"
MK]1S? X[&8C'TJU/&4L/6I+&4HU_98NE6]C456*:7O*+^U'4%>-^[' ! &2.
M,>YSC/8CG'!/P-^SB+6^_:'^,6J:,%?18X_$82>%<P?\3/Q?:/;-"ZDH([N3
M3=3N(.@EB4R0YC! ;XI_:,\7_%>.;P=\#_"/B'[3J2O:WGB&1[--0MK:X5(Y
M5MI+.ZGTO0"Z,RR:M>ZMYMHC++$MK<+#(OT9\"/@_!\(?##Z=(\-YX@U66&[
M\0:A:QA;1Y+>%H[#3;)Y!%.VG:3%)+#;M)%"9IIKJ[^SV_VD1I$:$\GR_,88
MM1I8S,Z='#T\&ITY5848UU7J5\1&-22HV<>2G3G:K*[=MXK6>-H\7<1Y#5RB
MG4Q&4<.XO%9EB\Z]E5IX.MBJV#JX'#Y?E\Z]"A/%2YJCJXJI2I^QA344YN\9
MOYW_ &CC#9_'_P"#-_K1":''%H!>:?\ X](9;;QG)+>32N?E$<,L^DR3,6"1
M(8I9\Q+F/[SB0%$+*RDKN926&&ZE6&<$[N&XZY''!KQ7X[_""'XN>&8;&*2"
MUU_1I)K[P_J%P&%JL\\:I=Z;>O&&E33]36&!)Y8HY'MYX;2\2*;R'B?YN\*_
MM%>,/A4D'@_XW^#_ !";O2DAL;37H$L_MMS;VX\J%9VN;F+2==555$BU73]5
M,EP"KSI-+OF9RH2S?+LNA@W&KC<NIU\+6P//&%65*>(E7I5Z"G.G"JI^TG&J
MHR]HI0A=>]&]1QU/A+B//JN;QKTLIXBQ&$S+!YPJ-6O@\-BL/@:6"Q&7XZI0
MIU:F&=Z4:V%J3ISIRC.HKP2E)?H&02#QCIQQZ<_3Z]>@[&OS]_:WO;.#XF?!
MQ;*14UNQE-W=R0<3P6<OB?PP^@&9L??%W9:_-;X.55;@D,)!GJ]<_;+\(2P&
MS\'>%O$?B/6[A6CM;6_@M=/M=[J5#%+"]U34[K#DJ8+:U17 )6X4%7KY@\9>
M$OBQ<^)O"7CGX@Z7J#:OXU\0P7*6D5C,]UI6GZ)J6@I EY9VL<\6BV3Q:D8]
M,T^XD2\C@LKJYOT2:1V;LR3*<1@<4\3F<88!*AC*="A7J4H8C$U*N#Q-/]W2
M]I-JC24G.K.I*$+\D(WE*Z\7CCBG 9QE#RW(9SS9RQ^4UL=F&"HXBK@LLP]'
M,\#4IU)XF6&A3EBJN(E0A1I4?:U(1C5J5'"*Y7^NT@_=MP#Q[=,_T%?GS^SK
MI5E>_M ?&/4;B)9+K1]2\8#3V;($+:KXZU"TNY!CDR-;0&!3VCGE!(+ C]!)
MFVQMDA0>K'H 3@#ZGI]3[BOA;]G*PU"W^-?QRN+K3[^UM[C4M=:WGN[*ZMH)
MU;Q[J\P:":>*..93"5D!B9\QE7&59<^3ELE#+N(%S*+J8#!PBN9*4[YC#FC%
M)IR]QOF4?LN\K+4^LXDI>TS_ (%<H<U.&>8^4FX2E"$HY+B73E)J#C!JI&+A
M*4X/G4>5\R2?W0.$QP  5P"0   V. 2. >V2,#([?GM^U#8Z=?\ QA^$]MXA
M>:'PGJ>G6^FWEPLHM_(@E\3^1KCI=.KI#)'%=Z5-/* 3%$JR283::_0B'_5J
M!QN#=\]AC.._ZX["O$?CI\'K/XN>%1IJR6]CX@TN62[\.ZE<H7MXIKB$07NG
MWPCWR?V9JD*I#>%(I6CDBMKE8+@VPC?/)\72P694:M9NG1E"O0J58QYI4/K-
M"5"->*M*[I2G&3Y4VK-K9I]'&.4XC.<@Q.%PE.-;$TZV78^GA:C2AC?[/QE+
M%U<%+F:IWQ=&%>A!U'&FJDUSR2UCPG_#(/PD;[R^+&(;DMXD)(/&[D6(+'.2
MS')SW)R*</V0/A%G.SQ7D9Q_Q4AYZ=,V&.V1D@#&3@XKROPK^T7XP^$Z0^#/
MCCX1UUKC3D2SL_$<$MH]_<6\$>R$7,MY=0:5K^T*J1ZK9ZMY]RB%KA)YW:5N
MIUK]LOP:8/LW@[PQXC\1ZU<%H;2TOHK/3;<S,GR;X;2]U;5;H E2Z6]DB3 E
M$N%+9'J3I\61G[*GB,5B:<K^RQ5'%T)86I!W:JNLYQC3BXR3<9Q4HM233:][
MY*&-\+)4E/%9=DV78F.F(RS'9=BJ6:8:O=JIAY82-"LZU2G.\)2H5*]*3Y7&
MI)2;.ULOV3?A7IFH:=JMJ/%D=[I5]9:C92_\)!O\FYL;N*^MI,O8<JMQ"CNA
M8!@,$= "N*^"WPK\?>(O&4OQB^+TEY!JTI,_A[P[+++ ULYB$$.H7>FK.T6F
M6EC:$6VD:5<&2\WR37VI+'<%3<E>7F-?&4JT:$LTEF$Z-.,:E2,VJ5&JWS5*
M%&=N6K&$MZL%&$I-\JT/I<@P.5XC O%4^$\/DM'$UIU,/0K4J4,5B,/&T*.,
MQ5"BF\-4KTTI4Z%:I5K0H.G[246_9P^FI/&]JWC:'P&UG<C4I_"S^+EO0R&Q
M^QV^M6^BO:C+K<_:C=W,4B_N# +<LS3K)MB:[>:+X>ULQS:KH6AZG($)634-
M,L+\'S6VD1S36]QG(5=Q1SG@GC KYN\<>"M$\:_M">!=.\6:A>3>%[_X2>.8
M4\-&=[+2O'VKZ)XS\(78TG6WM6MKC4K'PU8WTNJMX8DE6QUY;XWVI6NJ6GAV
M=+?3USPEX=^%'Q#^%[_#.PC\-7'CK7]5\.^)O!6BW+6^@^)/#MGX;U;5KOQ+
M-X>D:2QLM6\(7UOI\W_"5:7!:7LUKJ3Z#JUS>0:CIL$7Y]A\[S*E7S*O7P]+
M^S\%GKRI5J6+5+'RH5ZF3T,+.EA:%!QE&G6S6%H5\72QF*I1Q&(HTG1A2IU?
MTRME&6XK#Y=2I8B=3&XW(H9K/#U\+2JX%5L-1SVOBZ-3%5JTU1G.EE+<9T<%
M7PF"JNC0Q%7VU6<Z/OFFW>FVTVI:5IFE-ID&D7$-I.$T2ZT;3YY)+.WOE?2[
MB6PM;#5[1+>Z2.YN]+DO+:UODN--N)8KZ":WCZ%+XR3"/8NQTD=?W@+,B[?F
MPIX4@D@G) [#!Q\I7/B;QAHJ_M=ZUX;M;OQ'XB\(M#JO@SP]<-<7UO<:S:?
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MAT;6Y7BA;4M+O#8_V]X?ELIY=,U*PM;K5X-0\=U3PWXI^)_Q?^*$.L6?P_\
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3.4I-1C%*,8IJ,8I1C&,4HK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>dare-20250814.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWauF2bP9z5Z8iekhvWB9bUm6vyAn2sB8YSwRpx6W8ZoB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:DARE="http://darebioscience.com/20250814" elementFormDefault="qualified" targetNamespace="http://darebioscience.com/20250814">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://darebioscience.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="dare-20250814_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="dare-20250814_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>dare-20250814_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>dare-20250814_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="dare-20250814.xsd#Cover" roleURI="http://darebioscience.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://darebioscience.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 14,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DARE
BIOSCIENCE, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001401914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-4139823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3655
Nobel Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">926-7655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DARE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dare-20250814.xsd</File>
    <File>dare-20250814_lab.xml</File>
    <File>dare-20250814_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "DARE",
   "nsuri": "http://darebioscience.com/20250814",
   "dts": {
    "schema": {
     "local": [
      "dare-20250814.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "dare-20250814_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dare-20250814_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://darebioscience.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-08-14",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-14",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001641172-25-023971-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-023971-xbrl.zip
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MM)+/B%55H-]E):BHQ?;[Y<U-U^*3V*PVB;]6."-BRW\!4$L#!!0    ( #N
M#EN^#9&'7 <  .!7   5    9&%R92TR,#(U,#@Q-%]P<F4N>&ULS9S?<]HX
M$,??;^;^!Q_W3 BDUVMH<IV4A@[3M,F%M+V[EXZP!6@B2XPD!_CO3[(QY8<E
M;UZ\R4-"S$K:[V=EV6M)OGBW2GGT1)5F4ERVNB>GK8B*6"9,S"Y;7\?MJ_%@
M-&I%VA"1$"X%O6P)V7KWUZ^_1/;GXK=V.QHRRI-^]$'&[9&8RK?1%Y+2?O21
M"JJ(D>IM](WPS!V10\:IB@8R77!JJ/VB:+@?O3[IDJC=!E3[C8I$JJ_WHVVU
M<V,6NM_I+)?+$R&?R%*J1WT2RQ16X=@0D^EM;:>KT\U/4?R",_'8=[\F1-/(
MXA*ZO]+LLN7:W32[/#N1:M;IG9YV._]\OAG'<YJ2-A,.6TQ;92E72U6Y[OGY
M>2?_MC0]LEQ-%"_;..N4[FQKMM^R@/V.)YKU=>[>C8R)R:->VTSDM7#_M4NS
MMCO4[O;:9]V3E4Y:)?R<H)*<WM-IE,OLF_7"]B3-7$=H;8[-%9U>MA*B7$6]
M/T[?=%^Y:GX?2-L_6Y&KP(9]ZZXSG#"I8V8[+'7Q[CB3SL:\L]?Z0E%-A<D%
MW]@#>V[0E;&=BB:E(ZX::#.;>IAQ138=IQNU72_+4MNB_5A8;MPI'>(RWO.!
MNVA(M<^B[-DY<TWCDYE\ZB246?:]5^Z# U5 LO_\R!NZFFBC2&S*FCB94)[7
M_\/:')AT&O"J)/%@:ZQV:M_BT*?=T%VI.)(JH<JR+NLB*MX+V'$GW5AT%C:4
MPK3C.>/;6$^53'UT-B2DQ]%=4+:)9FA>V?83Y\.0DUDUS@,3(,\N!M!*-5A$
M/U =*[9P7&K [ED"^?90^59H:QAS>>[<TQES_CI7W*67NH/A<<%3! C^#'.D
M"*I%BL"5$!GA]W0A50WX?4L@[U>8O*NT(6'^.R/*4,77$-)'QD#8?V#"]BA$
MXOV@B-#,\8$ /[8&$G^->N/AT8B$?#RGG+MLC@A0+Z^R!V+_$Q.[7^<+ '_]
MY*[O]M("9[]3!(C_S4O!?Z06*0)W5#&9V$NZ K _,@92/\>D[E&(ROM:)%#:
M6U-P_H,/^T >$NHATS'AA4=#>TR'<5>80Y&CY)RU,E&Q_TN) D/?,88B1TE#
M:R0V#'R0*;7G3'!4\5M#D:,DH'4B&V9^+0PS:_?X_TN63GX^.-UG?6P%98R2
M=/I$H; MGS0(XZ8U0GP/+:&,47+-D#@4S@.K1Q$^$@E=?:+K$.@C4RAIE!PS
M* \%]9UB*5'K,8OK!XUC6RALE,PR+!"%]@-9C1*KBDU9,3%8#]U;!,H>):T$
MR44)P4C$4BWDSN/B@<SL^;@>R"0XI-<4A(8#)=]\AG24H%PEB<6E-W]NF*#=
M4"@JS<%S1'@!",A\(=A[S\/>@V-'R4-K9;X0[&?/PWX&QXZ2B];*Q,0^L!]O
MU8-<>F:@O<90Y"BY:(U$3.#YE>96W2GYQ(KU4774CTI T2.FJ&&QJ!V^N,A#
M>GMI">6-F*Y6B\/D?">U(?P_MJB[DZRVAS)'3%Q#0IM^P%C$W3VT\"TE.C"!
M\D7)52OE-(W415A1XN^^^Q90H"@):)68AGG>2#?W,9<B^#SVV K*%263](EJ
M>N!URXFU]]3?^1J\@@UE6#V4T3#&[XH9Z\% IFDF-L]H/+-B'E,H7I3T+RBO
M8=1CR5G,#!.SS_8.43'"JSE7V4$AHR1[?F$-$[Y3U$7:;2'(UW&Y_0;J=CKU
MC;PA>RAQE%RO7B@N^9'6&57/Y5]1"AH%E+0/*KKI<8;&F1WVUMW>Y,'MF/&,
M,D=64-8H*9]/5,-LO\@'1=RVO?$ZG4CNWQY2:0@EC)+@!:0U#'G/CVJ\!R90
ML"B97:4<I#'A>A7/B9A1_^J%:DLH8)1,+R0.;>R=@<;>V3/'7I2,SR<*B6VQ
M-MR>4;<3SF;$OY,L6 "\SP:3>$!JT_OW\BT_;D>W2G,_AO9#-7:/*10XSA;)
MD+RF46<),S0I7!HR041L4ZKMOC9/=EY?"AH G#V40-$HC_>_4\X_";D48TJT
M%#0I;O5#3_B]1:!10)Q#K)&+$H)ODF>6DLH7@BK/.> QA2)'G#OTR,-9>UDL
M:MY>>XI7=X2(^TI P2-.(H;%(JU/,]3YS)[H!V+(QL,0?U\)*'_$"<6P6+3U
M\VI@+SPS&9XS/S"$TD9<"ELI#07R."6<O\\T$U0'QY8#0RADQ#6OE=)0(%^G
M5,WLH/91R:69;_9VAF!["D"A(ZYL#4K%@;_ZN8^\V/\6)%]A#7X[ 2)VKTBL
MUV[$L5M(45S)14*4AWK('LH==6.E7VC#Y&_-G*K=^Z?<F9'-VT*+'NI+0:.
MDJY"1>-<6W=V\@<OK7MV4-Z(B6F5,)P]4]F$LWC()0G>E^^90?DB9J$5LE#P
MOB?B464+$Z_OE(PI==,G>GNV 1(B8 70D"#FI\]"@?.X0*:IVTPDX\?QW(K6
MMYG)7V1J_0L^- B6@X8&<Q,G0#C279#^N=&+)N_7]W1*E5NF\$!7YKUMZ#%\
M4P0H#HT/ZAN%P!@JPG31.=)U8P^X=]46W[A?[GVL]LC_4$L#!!0    ( #N
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M93/&P)A0 *Y6V[:NT%XV\%VZ<"!8GR(5#NC\010(U*P31T1Q2EH^@#B+@90
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M?3 $6R1.ZM+*9QAIDOE?MH[/%C&8A#=@O0% &Y1 34'6'[)_F/YP>*M  8[
M_P-_*39_'V?)!F7#L 'J#;3FJE"KT6&7BG@F$AXAL,*:;0@6UYOCJG+!57K
M(*"6X1, _XB*VJVZHG:F%;5;=47M4E34+J5\F&)>XIV,L4RP<2GE%^K$NTY
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MM!@0@:_Z&.6P#[2G=^MG\EOIZYX3Y<=$,3B5FXDNED07!;\I0#:&@FDGI66
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M2;5N 7)/AL6),45A45VY]MWUV\TEF4PGTE+_$)8Y8>N_GVCNS[=%9L6XSGT
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MCB+;2>ET)G5U\JVM]-F )C3#=JBAL&DG73-NE\/'M].F,M>U4%-\,ADDFUH
M#6_568=@XYV4]S+4U(ELFO>:.I.FFFWFI$SA(3R\%M,.HV5M,X@S4,BN#EO?
M9LV=Z/:SIBF'4\/NFGQ '1 A0LHGTE)"V@D 2=A,"0&"S\F>>?\HG&(BFYG
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M]IV!7OY_4$L! A0#%     @ .X .6V,$+_\L P  ] L  !$
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7;5!+!08     !0 % #8!  "A50     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dare-20250814.xsd" xlink:type="simple"/>
    <context id="AsOf2025-08-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2025-08-14</startDate>
            <endDate>2025-08-14</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-08-14" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-08-14" id="Fact000004">0001401914</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-08-14" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-08-14" id="Fact000010">2025-08-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-08-14" id="Fact000011">DARE BIOSCIENCE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-08-14" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-08-14" id="Fact000013">001-36395</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-08-14" id="Fact000014">20-4139823</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-08-14" id="Fact000015">3655 Nobel Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-08-14" id="Fact000016">Suite 260</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-08-14" id="Fact000017">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-08-14" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-08-14" id="Fact000019">92122</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-08-14" id="Fact000020">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-08-14" id="Fact000021">926-7655</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-08-14" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-08-14" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-08-14" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-08-14" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-08-14" id="Fact000026">Common     stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-08-14" id="Fact000027">DARE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-08-14" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-08-14" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
